Warfarin treatment normalized D-dimer levels in patients with chronic atrial fibrillation, indicating it effectively reduces thrombotic risk.
Does warfarin treatment reduce markers of thrombogenesis in patients with chronic atrial fibrillation?
Warfarin treatment normalizes elevated D-dimer levels in patients with chronic atrial fibrillation, suggesting its utility as a marker for assessing reduction in thrombotic risk.
Absolute Event Rate: 0% vs 0%
Increased median plasma fibrinogen and vWF levels were found in patients with chronic atrial fibrillation. Plasma D-dimer levels were also increased in patients with chronic atrial fibrillation not receiving warfarin, suggesting increased intravascular thrombogenesis in such patients. Introduction of warfarin normalised circulating fibrin D- dimer levels, suggesting that warfarin treatment was effective in preventing excessive fibrin turnover, consistent with the antithrombotic effects of warfarin. These results suggest three possible thrombotic markers to assess patients with atrial fibrillation who are at high risk of thrombogenesis; D-dimer also merits assessment as a measure of reduction in thrombotic risk in patients receiving warfarin.
Lip et al. (Thu,) reported a other. Warfarin treatment normalized D-dimer levels in patients with chronic atrial fibrillation, indicating it effectively reduces thrombotic risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: